OncologyKnife fightData as of 2026-09-04
Acute Myeloid Leukemia is one of the more crowded fields on the map: 15 companies in the clinic, ranking it 2nd of 299 indications by competitor count. The median competitor is worth $1.2B, below the $1.20B median of the universe.
That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.
No one owns the field: the largest company, TNGX, holds only 19% of the $20.6B competing here.
$7.0B of allocated capital sits in Acute Myeloid Leukemia, 27th of 299 indications, and 1 of the 15 companies are pure plays that trade on this indication alone.
| Ticker | Company | Lead asset | Phase | Trials | Market cap | Pure play | Indications | Next catalyst |
|---|---|---|---|---|---|---|---|---|
| TNGX | Tango Therapeutics | Ivosidenib | Phase 3 | 2 | $3.8B | No | 5 | 23 Oct 2026 |
| SLS | SELLAS Life Sciences Group | Galinpepimut-S | Phase 3 | 3 | $2.8B | Yes | 1 | 25 Sep 2026 |
| HCM | HUTCHMED (China) | HMPL-306 | Phase 3 | 2 | $2.5B | No | 6 | No dated event |
| SNDX | Syndax Pharmaceuticals | Revumenib | Phase 3 | 8 | $1.8B | No | 4 | 31 Dec 2026 |
| AAPG | Ascentage Pharma Group International Unsponsored | APG-2575 | Phase 3 | 2 | $1.6B | No | 9 | No dated event |
| KURA | Kura Oncology | Ziftomenib | Phase 3 | 8 | $1.2B | No | 2 | 31 Dec 2026 |
| RIGL | Rigel Pharmaceuticals | Olutasidenib | Phase 2 | 1 | $897M | No | 3 | 31 Dec 2026 |
| PGEN | Precigen | PRGN-3006 T Cells | Phase 1 | 1 | $2.5B | No | 3 | No dated event |
| CGEM | Cullinan Therapeutics | CLN-049 | Phase 1 | 1 | $1.4B | No | 8 | 14 Sep 2026 |
| GERN | Geron | Imetelstat | Phase 1 | 1 | $970M | No | 4 | 31 Dec 2026 |
| MGNX | MacroGenics | MGD024 | Phase 1 | 1 | $270M | No | 3 | 30 Sep 2026 |
| CLLS | Cellectis S.A. | UCART123v1.2 | Phase 1 | 1 | $239M | No | 3 | 31 Dec 2026 |
| DTIL | Precision BioSciences | CD123 targeted CAR-NK cells | Phase 1 | 1 | $203M | No | 16 | 31 Dec 2026 |
| NKTX | Nkarta | NKX101- CAR NK cell therapy | Phase 1 | 1 | $200M | No | 4 | 31 Dec 2026 |
Sorted by phase, then by market capitalisation. Ticker links open the company profile. Showing the 14 largest of the 15 companies competing in this indication. TNGX holds 19% of the $20.6B competing in this indication.
Crowded and cheaply priced. Six or more competitors and a median company below the universe median.
Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.
See every Oncology indication on the map15 US-listed companies in the $100M to $20B market cap band run clinical programmes in Acute Myeloid Leukemia. The largest and most advanced are Tango Therapeutics (TNGX, Ivosidenib, Phase 3); SELLAS Life Sciences Group (SLS, Galinpepimut-S, Phase 3); HUTCHMED (China) (HCM, HMPL-306, Phase 3); Syndax Pharmaceuticals (SNDX, Revumenib, Phase 3); Ascentage Pharma Group International Unsponsored (AAPG, APG-2575, Phase 3). The table on this page lists the 14 largest of them.
Of the 15 clinical-stage programmes in Acute Myeloid Leukemia, 6 are in Phase 3 or filed, 1 is in mid-stage development and 8 are in early-stage development.
The median company developing a drug for Acute Myeloid Leukemia is worth $1.2B, against a median of $1.20B across the whole universe. $7.0B of allocated capital sits in the indication, ranking it 27th of 299.
The next dated catalyst in Acute Myeloid Leukemia is CGEM on 14 Sep 2026. 12 dated events across the field fall in the next 12 months.
Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.
Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.
Back to the disease map